Searching for Optimal Dose-Volume Constraints to Reduce Rectal Toxicity after Hypofractionated Radiotherapy for Prostate Cancer

Clinical Oncology

Volumn 22, Issue 10, 2010, Pages 810-817

  Faria, S ^a   Joshua, B ^a   Patrocinio, H ^b   Dal Pra, A ^a   Cury, F ^a   Velly, A M ^b   Souhami, L ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

Dose volume constraints; DVH; Late rectal toxicity; Prostate cancer; Radiotherapy

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; FOLLOW UP; HISTOGRAM; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RADIATION INJURY; RECTUM DISEASE; RISK FACTOR;

AGED; DOSE FRACTIONATION; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY DOSAGE; RECTAL DISEASES; RECTUM; RISK FACTORS;

EID: 78149498360     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2010.08.005     Document Type: Article

References (41)

1. Williams M.V., Denekamp J., Fowler J.F. A review of alpha/beta ratios for experimental tumors: implications for clinical studies of altered fractionation. Int J Radiat Oncol Biol Phys 1985, 11:87-96.
2. Fowler J.F., Ritter M.A., Chappell R.J., et al. What hypofractionated protocols should be tested for prostate cancer?. Int J Radiat Oncol Biol Phys 2003, 56:1093-1104.
3. Brenner D.J. Hypofractionation for prostate cancer radiotherapy-what are the issues?. Int J Radiat Oncol Biol Phys 2003, 57:912-914.
4. Fiorino C., Sanguineti G., Cozzarini C., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 2003, 57:953-962.
5. Fonteyne V., De Neve W., Villeirs G., et al. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007, 84:156-163.
6. Huang E.H., Pollack A., Levy L., et al. Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2002, 54:1314-1321.
7. Jackson A., Skwarchuk M.W., Zelefsky M.J., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 2001, 49:685-698.
8. Koper P.C., Heemsbergen W.D., Hoogeman M.S., et al. Impact of volume and location of irradiated rectum wall on rectal blood loss after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 2004, 58:1072-1082.
9. Miralbell R., Taussky D., Rinaldi O., et al. Influence of rectal volume changes during radiotherapy for prostate cancer: a predictive model for mild-to-moderate late rectal toxicity. Int J Radiat Oncol Biol Phys 2003, 57:1280-1284.
10. Peeters S.T., Lebesque J.V., Heemsbergen W.D., et al. Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 64:1151-1161.
11. Pollack A., Zagars G.K., Starkschall G., et al. Prostate cancer radiation dose response: results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53:1097-1105.
12. Skwarchuk M.W., Jackson A., Zelefsky M.J., et al. Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 2000, 47:103-113.
13. Tucker S.L., Dong L., Cheung R., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 2004, 60:1589-1601.
14. Vavassori V., Fiorino C., Rancati T., et al. Predictors for rectal and intestinal acute toxicities during prostate cancer high-dose 3D-CRT: results of a prospective multicenter study. Int J Radiat Oncol Biol Phys 2007, 67:1401-1410.
15. Wachter S., Gerstner N., Goldner G., et al. Rectal sequelae after conformal radiotherapy of prostate cancer: dose-volume histograms as predictive factors. Radiother Oncol 2001, 59:65-70.
16. Benk V.A., Adams J.A., Shipley W.U., et al. Late rectal bleeding following combined X-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys 1993, 26:551-557.
17. Martin J.M., Rosewall T., Bayley A., et al. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 2007, 69:1084-1089.
18. Boersma L.J., van den Brink M., Bruce A.M., et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998, 41:83-92.
19. Fiorino C., Fellin G., Rancati T., et al. Clinical and dosimetric predictors of late rectal syndrome after 3D-CRT for localized prostate cancer: preliminary results of a multicenter prospective study. Int J Radiat Oncol Biol Phys 2008, 70:1130-1137.
20. Greco C., Mazzetta C., Cattani F., et al. Finding dose-volume constraints to reduce late rectal toxicity following 3D-conformal radiotherapy (3D-CRT) of prostate cancer. Radiother Oncol 2003, 69:215-222.
21. Kupelian P.A., Reddy C.A., Carlson T.P., et al. Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume?. Cancer J 2002, 8:62-66.
22. Ryu J.K., Winter K., Michalski J.M., et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy). Int J Radiat Oncol Biol Phys 2002, 54:1036-1046.
23. Michalski J.M., Purdy J.A., Winter K., et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000, 46:391-402.
24. Zapatero A., Garcia-Vicente F., Modolell I., et al. Impact of mean rectal dose on late rectal bleeding after conformal radiotherapy for prostate cancer: dose-volume effect. Int J Radiat Oncol Biol Phys 2004, 59:1343-1351.
25. Beckendorf V., Guerif S., Le Prise E., et al. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity. Int J Radiat Oncol Biol Phys 2004, 60:1056-1065.
26. Rene N., Faria S., Cury F., et al. Hypofractionated radiotherapy for favorable risk prostate cancer. Int J Radiat Oncol Biol Phys 2010, 77(3):805-810.
27. Trotti A., Colevas A.D., Setser A., et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003, 13:176-181.
28. Radiation Therapy Oncology Group RTOG 0126. A phase III randomized study of high dose 3D-CRT/IMRT versus standard dose 3D-CRT/IMRT in patients treated for localized prostate cancer. Available at http://www.rtog.org.
29. Radiation Therapy Oncology Group RTOG 0415. A phase III randomized study of hypofractionated 3D-CRT/IMRT versus conventionally fractionated 3D-CRT/IMRT in patients with favorable-risk prostate cancer Available at:. http://www.rtog.org.
30. PROFIT Canadian prostate fractionated irradiation trial Radiation Therapy Oncology Group Available at:. http://clinicaltrials.gov/ct/show/NCT00304759%3Forder%3D11.
31. Storey M.R., Pollack A., Zagars G., et al. Complications from radiotherapy dose escalation in prostate cancer: preliminary results of a randomized trial. Int J Radiat Oncol Biol Phys 2000, 48:635-642.
32. Faria S.L., Souhami L., Bosede J., et al. Reporting late toxicity in prostate cancer patients treated with curative radiation treatment. Int J Radiat Oncol Biol Phys 2008, 72:777-781.
33. Clark B.G., Souhami L., Pla C., et al. The integral biologically effective dose to predict brain stem toxicity of hypofractionated stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 1998, 40:667-675.
34. Kuban D.A., Tucker S.L., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:67-74.
35. Zietman A.L., DeSilvio M.L., Slater J.D., et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294:1233-1239.
36. Dearnaley D.P., Sydes M.R., Graham J.D., et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007, 8:475-487.
37. Cury F.L., Shenouda G., Souhami L., et al. Ultrasound-based image guided radiotherapy for prostate cancer: comparison of cross-modality and intramodality methods for daily localization during external beam radiotherapy. Int J Radiat Oncol Biol Phys 2006, 66:1562-1567.
38. Poli M.E., Parker W., Patrocinio H., et al. An assessment of PTV margin definitions for patients undergoing conformal 3D external beam radiation therapy for prostate cancer based on an analysis of 10,327 pretreatment daily ultrasound localizations. Int J Radiat Oncol Biol Phys 2007, 67:1430-1437.
39. Yan D., Xu B., Lockman D., et al. The influence of interpatient and intrapatient rectum variation on external beam treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2001, 51:1111-1119.
40. Garg A.K., Mai W.Y., McGary J.E., et al. Radiation proctopathy in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 2006, 66:1294-1305.
41. Goldner G., Zimmermann F., Feldmann H., et al. 3-D conformal radiotherapy of localized prostate cancer: a subgroup analysis of rectoscopic findings prior to radiotherapy and acute/late rectal side effects. Radiother Oncol 2006, 78:36-40.